An interventional study of Growth hormone in Infertility,Female, sponsored by Reproductive & Genetic Hospital of CITIC-Xiangya. Status unknown at 1 site in China. Open to female participants aged 20 Years to 39 Years. Per ClinicalTrials.gov, last updated 2022-01-11.
Sponsored by Reproductive & Genetic Hospital of CITIC-Xiangya · Not applicable, Interventional, and Treatment
GH plays an important role in the synthesis of ovarian steroid hormone and follicular development as a paracrine hormone.GH can regulate the growth hormone receptor and strengthen the function of mitochondria to improve the quality of the female oocyte.In this study, a prospective randomized control was used to explore the effect of GH adjuvant therapy on embryo quality.
2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.
This study's planned enrollment of 128 is close to the median of 120 across 1,698 interventional studies indexed under Infertility.
Browse Infertility studies →Reproductive & Genetic Hospital of CITIC-Xiangya is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
3)Endocrine and metabolic diseases and adrenal diseases, such as diabetes, Cushing's syndrome,etc.; 4)People has allergy history of growth hormone product; 5)Participating in other clinical research; 6)Other conditions that researchers determined not fit to be enrolled.
Growth Hormone adding to controlled ovarian hyperstimulation
Drug: Growth hormone
regular controlled ovarian hyperstimulation
GH has been considered as a cogonadotropin, which plays an important role in the synthesis of ovarian steroid hormone and follicular development as a paracrine hormone.GH can regulate the growth hormone receptor and strengthen the function of mitochondria to improve the quality of the female oocyte.
Also known as: Experimental group
number of high-quality embryos at D3
number of embryos grading 6C-II and above 6C-II at the third day after oocyte retrieval
Time frame: the third day after oocyte retrieval
proportion of high-quality embryos at D3
proportion of embryos grading 6C-II and above 6C-II at the third day after oocyte retrieval
Time frame: the third day after oocyte retrieval
clinical pregnancy rate
proportion of patients with presence of a gestational sac with fetal heartbeat by transvaginal ultrasound at 28 days after ET in transplanted patients
Time frame: 28 days after embryo transplanted
number of high-quality oocytes
number of oocytes with diameter ≥18mm at triggering day
Time frame: four months
implantation rate
proportion of implanted embryos in transplanted embryos
Time frame: 28 days after embryo transplanted
total amount of Gn used
total amount of Gn used
Time frame: four months
total days of Gn used
total days of Gn used
Time frame: two months
E2 levels at triggering day
E2 levels at triggering day
Time frame: four months
IGF-I level at the first day of injecting GH and befor injecting GH(GH group)
IGF-I level at the first day of injecting GH and befor injecting GH(GH group)
Time frame: at the first day of injecting GH and befor injecting GH(GH group)
IGF-I level at the first day of injecting Gn and before injecting Gn
IGF-I level at the first day of injecting Gn and before injecting Gn
Time frame: at the first day of injecting Gn and before injecting Gn
IGF-I level at triggering day
IGF-I level at triggering day
Time frame: four months
number of blastocysts at the fifth,sixth or seventh day after oocyte retrieval
number of blastocysts formation after culturing at the fifth,sixth or seventh day after oocyte retrieval
Time frame: at the fifth,sixth or seventh day after oocyte retrieval
This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Reproductive & Genetic Hospital of CITIC-Xiangya